[Federal Register Volume 61, Number 237 (Monday, December 9, 1996)]
[Notices]
[Pages 64912-64913]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-31246]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 96M-0462]


Matritech, Inc.; Premarket Approval of the Matritech NMP22TM 
Test Kit

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its 
approval of the application by Matritech, Inc., Newton, MA, for 
premarket approval, under the Federal Food, Drug, and Cosmetic Act (the 
act), of the Matritech NMP22TM Test Kit. After reviewing the 
recommendation of the Immunology Devices Panel, FDA's Center for 
Devices and Radiological Health (CDRH) notified the applicant, by 
letter of July 2, 1996, of the approval of the application.

DATES: Petitions for administrative review by January 8, 1997.

ADDRESSES: Written requests for copies of the summary of safety and 
effectiveness data and petitions for administrative review to the 
Dockets Management Branch (HFA-305), Food and Drug Administration, 
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Peter E. Maxim, Center for Devices and 
Radiological Health (HFZ-440), Food

[[Page 64913]]

and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 
301-594-1293.

SUPPLEMENTARY INFORMATION: On November 7, 1994, Matritech, Inc., 
Newton, MA 02160, submitted to CDRH an application for premarket 
approval of the Matritech NMP22TM Test Kit. The Matritech 
NMP22TM Test Kit is an enzyme immunoassay for the in vitro 
quantitative determination of nuclear matrix protein NMP22 in 
stabilized voided urine. The Matritech NMP22TM Test Kit is 
indicated as an aid in the management of patients with transition cell 
carcinoma of the urinary tract (TCC/UT), after surgical treatment to 
identify those patients with occult or rapidly recurring TCC/UT. The 
Matritech NMP22TM Urine Collection Kit is intended for the 
collection, stabilization, and transport of human urine which will be 
tested using the Matritech NMP22TM Test Kit.
    On November 30, 1995, the Immunology Devices Panel of the Medical 
Devices Advisory Committee, an FDA advisory committee, reviewed and 
recommended approval of the application. On July 2, 1996, CDRH approved 
the application by a letter to the applicant from the Director of the 
Office of Device Evaluation, CDRH.
    A summary of the safety and effectiveness data on which CDRH based 
its approval is on file in the Dockets Management Branch (address 
above) and is available from that office upon written request. Requests 
should be identified with the name of the device and the docket number 
found in brackets in the heading of this document.

Opportunity for Administrative Review

    Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any 
interested person to petition, under section 515(g) of the act, for 
administrative review of CDRH's decision to approve this application. A 
petitioner may request either a formal hearing under 21 CFR part 12 of 
FDA's administrative practices and procedures regulations or a review 
of the application and CDRH's action by an independent advisory 
committee of experts. A petition is to be in the form of a petition for 
reconsideration under 21 CFR 10.33(b). A petitioner shall identify the 
form of review requested (hearing or independent advisory committee) 
and shall submit with the petition supporting data and information 
showing that there is a genuine and substantial issue of material fact 
for resolution through administrative review. After reviewing the 
petition, FDA will decide whether to grant or deny the petition and 
will publish a notice of its decision in the Federal Register. If FDA 
grants the petition, the notice will state the issue to be reviewed, 
the form of the review to be used, the persons who may participate in 
the review, the time and place where the review will occur, and other 
details.
    Petitioners may, at any time on or before January 8, 1997, file 
with the Dockets Management Branch (address above) two copies of each 
petition and supporting data and information, identified with the name 
of the device and the docket number found in brackets in the heading of 
this document. Received petitions may be seen in the office above 
between 9 a.m. and 4 p.m., Monday through Friday.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under 
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) 
and redelegated to the Director, Center for Devices and Radiological 
Health (21 CFR 5.53).

    Dated: November 7, 1996.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and 
Radiological Health.
[FR Doc. 96-31246 Filed 12-6-96; 8:45 am]
BILLING CODE 4160-01-F